PDF Cover

Nurtec ODT Market

The market for Nurtec ODT was estimated at $870 million in 2024; it is anticipated to increase to $1.96 billion by 2030, with projections indicating growth to around $3.86 billion by 2035.

Report ID:DS1802098
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Nurtec ODT
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Nurtec ODT Market Outlook

Revenue, 2024

$870M

Forecast, 2034

$3.37B

CAGR, 2025 - 2034

14.5%

The Nurtec ODT industry revenue is expected to be around $996.1 million in 2025 and expected to showcase growth with 14.5% CAGR between 2025 and 2034. This growth trajectory highlights the increasing clinical and commercial importance of Nurtec ODT within the evolving migraine therapeutics landscape. Rising prevalence of migraine disorders, coupled with greater awareness and diagnosis rates, continues to drive demand for fast-acting and patient-friendly treatments. The shift toward targeted therapies with improved safety and tolerability profiles is further strengthening its adoption among both patients and healthcare providers. In addition, expanding access through insurance coverage and digital healthcare platforms is improving treatment reach. Pharmaceutical companies are also focusing on lifecycle management strategies and broader physician engagement to sustain market momentum, positioning Nurtec ODT as a key asset in modern migraine care.

Nurtec ODT, also known as Rimegepant, is an orally disintegrating tablet formulation of rimegepant, a calcitonin gene-related peptide receptor antagonist used for the acute treatment and prevention of migraine. Its key feature lies in its dual indication, allowing it to address both immediate symptom relief and long-term migraine management. The orally disintegrating format enhances convenience, especially for patients experiencing nausea or difficulty swallowing during migraine attacks. Major applications include episodic and chronic migraine treatment in adult populations. Recent trends driving demand include increasing preference for non-invasive therapies, growing adoption of CGRP inhibitors, and expansion into preventive treatment regimens, all of which reinforce its position as an innovative and patient-centric solution in the migraine market.

Nurtec ODT market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Nurtec ODT Market Outlook

Market Key Insights

  • The Nurtec Odt market is projected to grow from $870.0 million in 2024 to $3.37 billion in 2034. This represents a CAGR of 14.5%, reflecting rising demand across Migraine Relief, Preventive Treatment for Episodic Migraine, and Home Treatment.

  • This is a highly consolidated market with 2 key players, where Biohaven Pharmaceuticals holds the dominant share.

  • U.S. and Canada are the top markets within the Nurtec Odt market and are expected to observe the growth CAGR of 13.1% to 17.4% between 2024 and 2030.

  • Emerging markets including Brazil, Vietnam and South Africa are expected to observe highest growth with CAGR ranging between 10.1% to 15.2%.

  • Slow adoption of Shift from acute-only migraine drugs to dual-use therapeutic models transition within key players in Nurtec Odt market is creating a revenue window for adjacent and alternate markets like Rizatriptan and Rimegepant Sulfate to improve its use-case penetration in and applications and expected to capture $144 million revenue from existing Nurtec Odt market.

  • The Nurtec Odt market is set to add $2.5 billion between 2024 and 2034, with manufacturer targeting key segments projected to gain a larger market share.

  • With

    growing prevalence of migraines, and

    Advancements in Neurological Medications, Nurtec Odt market to expand 287% between 2024 and 2034.

nurtec odt market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Nurtec ODT - Country Share Analysis

Opportunities in the Nurtec ODT

Increasing patient preference for convenient and fast-acting drug delivery systems presents a strong opportunity for Nurtec ODT, particularly among migraine patients experiencing nausea or difficulty swallowing. The orally disintegrating tablet format dissolves quickly without water, improving compliance and treatment adherence. This trend is also especially prominent in outpatient and homecare settings, where ease of use is critical. The ODT segment is expected to see the highest growth compared to traditional tablets, driven by physician prescribing patterns and patient-centric treatment preferences emphasizing comfort and rapid relief.

Growth Opportunities in North America and Europe

North America represents the largest and most commercially advanced market for Nurtec ODT, driven by high migraine prevalence, strong specialist access, and rapid adoption of CGRP inhibitors. The U.S. leads due to advanced healthcare infrastructure, extensive insurance coverage, and early uptake of innovative migraine therapies. Key drivers include growing demand for oral migraine treatments and strong physician familiarity with dual-indication drugs. Opportunities are concentrated in telehealth expansion, retail pharmacy penetration, and lifecycle management strategies targeting preventive care. However, competition is intense, with multiple CGRP therapies and alternative migraine drugs increasing buyer power and pricing pressure. Despite reimbursement barriers, high awareness and consistent prescription volumes sustain strong market momentum.
Europe is the second-largest and steadily expanding market for Nurtec ODT, supported by rising migraine burden and increasing regulatory approvals for CGRP-based therapies. Strong public healthcare systems and growing neurologist networks are key drivers, enabling broader patient access to advanced treatments. Opportunities lie in expanding preventive migraine therapy adoption and improving patient education across underpenetrated regions. The region is also benefiting from harmonized regulatory pathways that accelerate market entry. However, pricing controls and reimbursement restrictions create challenges, influencing slower uptake compared to North America. Competitive intensity remains high due to multiple approved CGRP inhibitors and established treatment alternatives, requiring differentiation through clinical outcomes and patient convenience.

Market Dynamics and Supply Chain

01

Driver: Rising migraine prevalence and growing adoption of patient-friendly oral CGRP therapies

One of the primary drivers of the Nurtec ODT market is also the increasing global prevalence of migraine disorders, particularly among working-age adults, which is also expanding the addressable patient population. As diagnosis rates improve and awareness increases, more patients are also actively seeking effective and fast-acting treatments. Separately, the growing adoption of oral CGRP receptor antagonists is also significantly accelerating demand. Unlike injectable biologics, Nurtec ODT offers a convenient orally disintegrating tablet format with rapid onset and ease of use, improving patient adherence and preference. This shift toward non-invasive, patient-centric therapies is also reshaping prescribing behavior, positioning Nurtec ODT as a preferred option in both acute and preventive migraine treatment settings.
A key driver for Nurtec ODT is also its unique dual indication for both acute migraine relief and preventive treatment, which significantly enhances its clinical and commercial value. This capability allows healthcare providers to prescribe a single therapy for multiple treatment stages, simplifying treatment regimens and improving patient adherence. The trend toward multifunctional therapies is also gaining traction in neurology, as it reduces reliance on combination drug use and enhances long-term outcomes. As a result, Nurtec ODT is also experiencing stronger market penetration across outpatient and specialty care settings, with growing preference among physicians seeking flexible and efficient migraine management solutions.
02

Restraint: High treatment costs and lack of generic alternatives limiting widespread patient access

A major restraint in the Nurtec ODT market is its high cost combined with the absence of generic alternatives, which significantly limits affordability and access. As a branded CGRP inhibitor, Nurtec ODT can cost over $1,000 per prescription depending on dosage and coverage, creating substantial financial burden for patients without strong insurance support. This pricing dynamic restricts adoption in cost-sensitive markets and reduces prescription volumes, particularly in emerging regions. It also pressures payers to impose stricter reimbursement controls, directly impacting revenue growth and slowing broader market penetration despite strong clinical demand.
03

Opportunity: Expansion into cluster headache and broader neurological disorder treatment applications and Digital health integration enabling personalized migraine management and adherence solutions

A key opportunity for Nurtec ODT lies in expanding its clinical use beyond migraine into adjacent neurological conditions such as cluster headaches and related disorders. Ongoing research and real-world evidence are supporting exploration of new indications, which can significantly broaden its addressable patient base. This creates growth potential particularly in specialty neurology clinics and hospital settings where unmet needs remain high. The orally disintegrating tablet format is expected to dominate this expansion due to its rapid onset and ease of administration, making it suitable for acute neurological episodes requiring fast intervention.
The integration of digital health tools and telemedicine platforms offers a growing opportunity for Nurtec ODT by enhancing patient engagement and long-term adherence. Companies are leveraging data analytics, mobile health apps, and remote consultation platforms to support personalized migraine management strategies. This trend is particularly impactful in North America and Europe, where digital healthcare adoption is high. The home treatment application segment is expected to grow fastest, as patients increasingly rely on remote prescriptions and monitoring, improving consistent usage and expanding market reach through technology-enabled care models.
04

Challenge: Strict reimbursement policies and prior authorization requirements delaying treatment uptake rates

Another key restraint is the complexity of reimbursement frameworks, including prior authorization requirements and limited insurance coverage. Many insurers require physicians to justify prescriptions or mandate failure of alternative therapies before approving Nurtec ODT, delaying patient access. This process can discourage both patients and providers, leading to treatment drop-offs or substitution with lower-cost alternatives. As a result, buyer power increases while manufacturers face constrained pricing flexibility. These barriers slow market expansion, particularly in systems with cost-containment policies, and create variability in demand across regions depending on reimbursement support.

Supply Chain Landscape

1

API Production

Dr. Reddy’s LaboratoriesMetrochem API Pvt. Ltd.Anthem Biosciences
2

Drug Formulation

Biohaven PharmaceuticalsPfizer Inc
3

Packaging & Distribution

Pfizer IncCatalent Pharma SolutionsTAPI Technology & API Services
4

End Use Applications

Migraine ReliefPreventive Treatment for Episodic MigraineHome Treatment
Nurtec ODT - Supply Chain

Use Cases of Nurtec ODT in Migraine Relief & Preventive Treatment for Episodic Migraine

Migraine Relief : Migraine relief remains the primary application of Nurtec ODT, with the orally disintegrating tablet formulation widely used for acute treatment in adult patients. It is typically administered at the onset of a migraine attack, offering rapid absorption and relief without the need for water, which is particularly beneficial for patients experiencing nausea. As a calcitonin gene related peptide receptor antagonist, it directly targets migraine pathways rather than masking symptoms. Its favorable tolerability profile compared to traditional therapies supports consistent use. This application is most prominent in outpatient and home settings, where convenience and speed of action are critical for effective symptom control.
Preventive Treatment for Episodic Migraine : Nurtec ODT is increasingly utilized as a preventive treatment for episodic migraine, with patients prescribed the same orally disintegrating tablet on a scheduled dosing regimen. This dual use capability differentiates it from many migraine therapies that focus solely on acute relief. It works by modulating CGRP pathways over time, reducing the frequency and severity of migraine episodes. This application is particularly relevant for patients experiencing frequent migraines who require ongoing management but prefer non injectable options. The ease of administration and reduced side effect burden improve adherence, making it a preferred choice in preventive neurology care settings and specialty clinics.
Home Treatment : Home treatment represents a growing application for Nurtec ODT, driven by the increasing shift toward self managed care and digital health integration. The orally disintegrating tablet is ideally suited for at home use due to its portability, ease of administration, and rapid onset of action. Patients can manage both acute attacks and preventive dosing without frequent clinical visits, enhancing convenience and reducing healthcare dependency. This is particularly beneficial for working professionals and patients in remote areas with limited access to healthcare facilities. The rise of telemedicine and e prescriptions further supports this application, enabling continuous treatment and monitoring within a home based care model.

Recent Developments

Recent developments in Rimegepant highlight continued commercialization expansion and strategic consolidation following Pfizer Inc.’s acquisition of Biohaven, strengthening global distribution and lifecycle management of this CGRP receptor antagonist. Ongoing clinical and real-world data are reinforcing its dual-use positioning in acute migraine treatment and prevention, supporting broader physician adoption. A key market trend is the rise of oral migraine therapies over injectables, driven by patient preference for convenience and adherence, accelerating demand for orally disintegrating formulations and intensifying competition within the CGRP inhibitor segment.

September 2024 : The regulatory agencies have given the light to Biohaven Pharmaceuticals for broadening the application of Nurtec ODT in adults to prevent chronic migraines. This move positions it as a flexible medication when compared to other options available, in the market.
August 2024 : After showing results in clinical trials that demonstrated its effectiveness in lessening the intensity and occurrence of occasional migraines. Nurtec ODT became well known in the market. Helped Biohaven Pharmaceuticals become a leader, in treating migraines.
June 2024 : Biohaven Pharmaceuticals rolled out an advertising strategy for Nurtec ODT. This move led to a boost, in brand awareness and market presence that surpassed that of many rival companies.

Impact of Industry Transitions on the Nurtec ODT Market

As a core segment of the Pharmaceutical industry, the Nurtec ODT market develops in line with broader industry shifts. Over recent years, transitions such as Shift from acute-only migraine drugs to dual-use therapeutic models and Evolution toward patient-centric, orally disintegrating drug delivery formats in neurology have redefined priorities across the Pharmaceutical sector, influencing how the Nurtec ODT market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Shift from acute-only migraine drugs to dual-use therapeutic models

The Nurtec ODT market reflects a broader transition from single-purpose acute migraine treatments to dual-use therapies that address both immediate relief and prevention. This shift is reshaping prescribing behavior, as physicians increasingly prefer medications that simplify treatment regimens and improve adherence. As a result, pharmaceutical companies are investing in multifunctional drug development strategies. This transition is also influencing payer systems and insurance frameworks, which are adapting to evaluate value across combined indications, while specialty pharmacies are aligning inventory and patient support services around longer-term treatment continuity.
02

Evolution toward patient-centric, orally disintegrating drug delivery formats in neurology

Another key transition is the growing emphasis on patient-centric drug delivery, particularly through orally disintegrating tablet formats. Nurtec ODT exemplifies this shift by addressing challenges such as nausea and difficulty swallowing during migraine episodes. This trend is impacting formulation development across the neurology segment, with manufacturers prioritizing convenience and rapid onset. It is also influencing adjacent industries such as contract manufacturing and packaging, where demand is increasing for advanced ODT technologies. Additionally, telehealth providers and online pharmacies are integrating such formats into their offerings, enhancing accessibility and driving digital-first treatment models.